Skip to main content

#156559

Anti-CD45 [OX1]

Cat. #156559

Anti-CD45 [OX1]

Cat. #: 156559

Unit size: 100 ug

Availability: 10-12 weeks

Target: CD45 (Leukocyte Common Antigen)

Class: Monoclonal

Application: FACS ; IHC

Reactivity: Rat

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: Medical Research Council; University of Oxford

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-CD45 [OX1]
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Rat
  • Host: Mouse
  • Application: FACS ; IHC
  • Description: The antibody is directed against L-CA, the rat equivalent of CD45 which has a molecular weight 180-240kDa, and is present on all rat leukocytes, but not erythroid cells or cells of other tissues.
  • Immunogen: A 100kD thymocyte glycoprotein fraction enriched for the rat leukocyte common antigen (L-CA)
  • Myeloma used: NS1
  • Recommended controls: IgG1

Target Details

  • Target: CD45 (Leukocyte Common Antigen)
  • Target background: The antibody is directed against L-CA, the rat equivalent of CD45 which has a molecular weight 180-240kDa, and is present on all rat leukocytes, but not erythroid cells or cells of other tissues.

Applications

  • Application: FACS ; IHC

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Dry ice

References

  • Woollett et al. 1985. Eur J Immunol. 15(2):168-73. PMID: 2578966.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.